News

INOVIO a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases,…
Read More...

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD)…
Read More...

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced that…
Read More...

Epizyme, Inc. a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHMED (China) Limited (“HUTCHMED”), announce a…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a…
Read More...

Kite, a Gilead Company and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer…
Read More...

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2…
Read More...

Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value,…
Read More...

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its…
Read More...

NRx Pharmaceuticals (NRx) announced it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human Vasoactive…
Read More...

BioNTech SE and Kite, a Gilead Company announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing…
Read More...

Novavax, Inc. a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has reached an agreement with the European Commission (EC)…
Read More...

EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera, a technology company with a centralized operating system for…
Read More...

Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical…
Read More...

As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with…
Read More...

Burning Rock Biotech Limited announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq…
Read More...

DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, and Catalent, the leading global provider of advanced delivery…
Read More...

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational…
Read More...

Ipsen and Exicure Inc. have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational…
Read More...